Endothelial dysfunction — A major mediator of diabetic vascular disease  by Sena, Cristina M. et al.
Biochimica et Biophysica Acta 1832 (2013) 2216–2231
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isReviewEndothelial dysfunction — A major mediator of diabetic vascular diseaseCristina M. Sena ⁎, Ana M. Pereira, Raquel Seiça
Institute of Physiology, Faculty of Medicine, University of Coimbra, Portugal
IBILI, Faculty of Medicine, University of Coimbra, Portugal⁎ Corresponding author at: Institute of Physiology, Su
Medicine, University of Coimbra, Azinhaga de Santa Com
Portugal. Tel.: +351 239 480013; fax: +351 239 480034
E-mail address: csena@ci.uc.pt (C.M. Sena).
0925-4439/$ – see front matter © 2013 Elsevier B.V. All r
http://dx.doi.org/10.1016/j.bbadis.2013.08.006a b s t r a c ta r t i c l e i n f oArticle history:
Received 19 February 2013
Received in revised form 31 July 2013
Accepted 20 August 2013
Available online 29 August 2013
Keywords:
Endothelial dysfunction
Endothelium
Diabetes
Vascular function
Oxidative stress
Potential therapeutic targetThe vascular endothelium is a multifunctional organ and is critically involved in modulating vascular tone and
structure. Endothelial cells produce awide range of factors that also regulate cellular adhesion, thromboresistance,
smooth muscle cell proliferation, and vessel wall inﬂammation. Thus, endothelial function is important for the
homeostasis of the body and its dysfunction is associated with several pathophysiological conditions, including
atherosclerosis, hypertension and diabetes. Patients with diabetes invariably show an impairment of endotheli-
um-dependent vasodilation. Therefore, understanding and treating endothelial dysfunction is a major focus in
the prevention of vascular complications associated with all forms of diabetes mellitus. The mechanisms of endo-
thelial dysfunction in diabetes may point to newmanagement strategies for the prevention of cardiovascular dis-
ease in diabetes. This review will focus on the mechanisms and therapeutics that speciﬁcally target endothelial
dysfunction in the context of a diabetic setting. Mechanisms including altered glucosemetabolism, impaired insu-
lin signaling, low-grade inﬂammatory state, and increased reactive oxygen species generation will be discussed.
The importance of developing new pharmacological approaches that upregulate endothelium-derived nitric
oxide synthesis and target key vascular ROS-producing enzymes will be highlighted and new strategies that
might prove clinically relevant in preventing the development and/or retarding the progression of diabetes asso-
ciated vascular complications.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
1.1. Vascular function and endothelium
The endothelium is a monolayer of cells covering the vascular
lumen. For many years this cell layer was thought to be relatively
inert, a mere physical barrier between circulating blood and the under-
lying tissues. It is now recognized, however, that endothelial cells are
metabolically active with important paracrine, endocrine and autocrine
functions, indispensable for the maintenance of vascular homeostasis
under physiological conditions [1,2]. The multiple functions of vascular
endothelium are summarized in Fig. 1 and include regulation of vessel
integrity, vascular growth and remodeling, tissue growth and metabo-
lism, immune responses, cell adhesion, angiogenesis, hemostasis and
vascular permeability. The endothelium plays a pivotal role in the regu-
lation of vascular tone, controlling tissue blood ﬂow and inﬂammatory
responses and maintaining blood ﬂuidity [3–5].
Endothelium-derived factors with vasodilatory and antiproliferative
effects include endothelium-derived hyperpolarization factor (EDHF) [],
nitric oxide (NO) [8,9] and prostacyclin (PGI2) [10], while endothelin-1b-unidade 1, Pólo III, Faculty of
ba, Celas, 3000-504 Coimbra,
.
ights reserved.(ET-1) [11], angiotensin II and reactive oxygen species (ROS) are
among the mediators that exert vasoconstrictor effects [12,13]. Endo-
thelial cells also produce antithrombotic (NO and PGI2 both inhibit
platelet aggregation) and prothrombotic molecules [von Willebrand
factor, which promotes platelet aggregation, and plasminogen activator
inhibitor-1 (PAI-1), which inhibits ﬁbrinolysis] [5].
As amajor regulator of vascular homeostasis, the endotheliummain-
tains the balance between vasodilation and vasoconstriction, inhibition
and promotion of the migration and proliferation of smooth muscle
cells, ﬁbrinolysis and thrombogenesis as well as prevention and stimula-
tion of the adhesion and aggregation of platelets (Fig. 2) [5]. Disturbing
this tightly regulated equilibrium leads to endothelial dysfunction.1.2. Nitric oxide
NO is a crucial player in vascular homeostasis. NO is synthesizedwith-
in endothelial cells during conversionof L-arginine to L-citrulline by endo-
thelial nitric oxide synthase (eNOS) [15]. It is released from endothelial
cells mainly in response to shear stress elicited by the circulating blood
or receptor-operated substances such as acetylcholine, bradykinin, or se-
rotonin [16]. NO diffuses to vascular smoothmuscle cells (VSMC) and ac-
tivates soluble guanylate cyclase (sGC), yielding increased levels of cyclic
guanosine-3,5-monophosphate (cGMP) and relaxation of VSMC [1,17].
Additionally, NOalsoprevents leukocyte adhesion andmigration, smooth
muscle cell proliferation, platelet adhesion and aggregation, and opposes
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Fig. 1.Multiple functions of endothelium.
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(Fig. 3) [18].
The half-life of NO is very short (less than 4 s). It is rapidly metabo-
lized to nitrite and then to nitrate before being excreted in the urine [4].
Alternatively, NO can also be an endocrine vasoregulator, modulating
blood ﬂow in the microcirculation [19]. Importantly, reduced eNOS ex-
pression and/or NO bioavailability is associated with endothelial dys-
function [20,21].Fig. 2. Endothelial cells are responsible for a number of physiological functions, including: 1) reg
2) control of blood ﬂuidity and coagulation through production of factors that regulate platelet a
processes through expression of cytokines and adhesionmolecules. ACh, acetylcholine; ATR, ang
NO, nitric oxide; PAI-1, plasminogen activator inhibitor-1; PGH2, prostaglandin H2; PGI2, prosta
TxA2, thromboxane A2; vWF, von Willebrand factor.1.2.1. Decreased formation of NO
eNOS is a dimeric enzyme depending on multiple cofactors for its
physiological activity andoptimal function. eNOS resides in the caveolae
and is bound to the caveolar protein, caveolin-1 that inhibits its activity.
Elevations in cytoplasmic Ca2+ promote binding of calmodulin to eNOS
that subsequently displaces caveolin and activates eNOS [22,23].
eNOS utilizes L-arginine as the substrate, and molecular oxygen and
reduced nicotinamide adenine dinucleotide phosphate (NADPH) as
co-substrates. Flavin adenine dinucleotide, ﬂavin mononucleotide,
tetrahydrobiopterin (BH4) and calmodulin are the cofactors [4]. A re-
duced expression and/or activity of eNOS could be responsible for a de-
crease in NO production. Oxidative stress leads to eNOS uncoupling, a
process where eNOS is converted from an NO-producing enzyme to an
enzyme that generates superoxide anion (O2•−).Mechanisms implicated
in eNOS uncoupling include oxidation of BH4 (a critical eNOS cofactor;
[24]), depletion of the enzyme substrate L-arginine, and accumulation
of endogenous methylarginines [25]. More recently, S-glutathionylation
of eNOS has also been proposed as a mechanism that leads to eNOS
uncoupling and decreased NO bioavailability [26]. Additionally, in-
creased expression of caveolin-1 in the endothelium (as described in di-
abetes and obesity [190]) leads to impaired activation of eNOS.
eNOS activity within the endothelial cell is also modulated by
circulating factors like insulin. Insulin is an essential hormone in
metabolic homeostasis with a vasodilator action exerted through
the phosphatidylinositol-3 kinase (PI-3K)/AKT pathway-dependent
eNOS activation [27]. Insulin can modulate eNOS activity by increas-
ing BH4 synthesis [28]. Insulin-stimulated endothelial dependent va-
sodilatation is impaired in insulin resistance [29,18]. Conversely,
eNOS plays a major role in the regulation of insulin sensitivity due
to the functions of NO in peripheral tissues [30]. Previous studies
have shown that mice lacking eNOS are more likely to develop insu-
lin resistance [227]. Apparently, modulation of eNOS phosphorylation
in mice is sufﬁcient to affect systemic insulin sensitivity indicating
that eNOS phosphorylation may be a novel target for the treatment of
insulin resistance [228].ulation of vascular tone through balanced production of vasodilators and vasoconstrictors;
ctivity, the clotting cascade, and theﬁbrinolytic system; and 3) regulation of inﬂammatory
iotensin-II receptor; BK, bradykinin; EDHF, endothelium-derived hyperpolarization factor;
cyclin; O2•−, superoxide anion; t-PA, tissue plasminogen activator; TM, thrombomodulin;
Fig. 3. Atheroprotective properties of nitric oxide generated by endothelial nitric oxide synthase.
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olism such as asymmetric dimethyl-L-arginine (ADMA) [1]. Following
oxidative stress or angiotensin II administration, the observed elevation
in ADMA levels reduces NO formation and leads to endothelial dysfunc-
tion. Indeed, in several prospective studies, ADMA has been noted to be
an independent predictor of cardiovascular events [33–35].
Another factor that regulates eNOS activity in the setting ofmetabol-
ic disease is adropin, which was recently recognized to be an important
regulator of energy homeostasis and insulin sensitivity. Lovren and col-
leagues [36] demonstrated that adropin is expressed in endothelial cells
and improves angiogenesis-related responses via activation of Akt,
eNOS, and extracellular signal regulated kinase 1/2. Like adiponectin
and leptin, adropin may be an endocrine factor that inﬂuences both
insulin resistance and endothelial functions such as vasodilation and
angiogenesis [36].1.2.2. Accelerated breakdown of NO
Accelerated degradation of NO by ROS is probably the major mecha-
nism impairing NO bioavailability in states of cardiovascular disease
[37,38]. In a diabetic milieu, an increment in O2•− levels is observed inWistar
GKWistar
GK
L
L
Fig. 4. In situ detection of superoxide in arterial vessels of normalWistar (left panels) and diabe
rescence after incubation with dihydroethidium. Representative ﬂuorescent staining of superox
sels (lower panels). O2•− formation signiﬁcantly increased in diabetic animals when comparedthe vasculature (Fig. 4). O2•− readily reactswithNO to formperoxynitrite
(ONOO−), reducingNObioavailability and contributing to impaired vaso-
relaxation [39]. Fig. 5 shows an increase in nitrotyrosine staining in the
aorta of a type 2 diabetic animalmodel, indicative of peroxynitrite forma-
tion. Additionally, lipid peroxyl radicals reactwithNOat almost diffusion-
limited rates and may be a source of NO inactivation [40]. Also, oxidized
low-density lipoprotein (LDL) cholesterol may react with endothelial
NO before it reaches the vascular smooth muscle cell and therefore re-
duce total NO-mediated vasodilation [41].1.3. Prostacyclin
PGI2 is the major metabolite of arachidonic acid produced by cyclo-
oxygenase in the endothelium. PGI2 activates adenylate cyclase, leading
to increased production of cyclic AMP and VSMC vasodilation. Addition-
ally, PGI2 is a potent antiproliferative agent in vascular smooth muscle
cells, and it reduces oxidative stress and prevents cellular adhesion to
the vascular wall [42]. PG12 also inhibits platelet aggregation. Clinical
and experimental models of diabetes are associated with decreased se-
cretion of PGI2 [3,27].L
L
tic Goto–Kakizaki rats (GK, right panels). Superoxide production was detected as red ﬂuo-
ide with dihydroethidium in the abdominal aorta (upper panels) and kidney arterial ves-
to age-matched controls.
Wistar
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Fig. 5.Nitrotyrosine (3-NT) immunoreactivity increases in arterial vessels from diabetic Goto–Kakizaki (GK) rats. Immunoﬂuorescence staining for 3-NT (green) in aortic (upper panels)
and kidney arterial sections (lower panels) isolated fromWistar (left panels) and diabetic GK (right panels) rats. Nuclei were counter-stainedwith DAPI (blue). The extent and intensity of
immunoﬂuorescence for nitrotyrosinewasmuchgreater in arterial rings fromdiabetic rat animalswhen compared to age-matched controls. MeasuringNT levels is thought to be a reliable
index to analyze peroxynitrite formation.
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There are smaller arteries in which endothelium-mediated vasodila-
tion is predominately affected by endothelium-dependent hyperpolari-
zation of vascular smooth muscle cells. The mechanism partially
responsible for the endothelium-dependent vasodilation of these arter-
ies, which persists in the presence of inhibitors of eNOS and prostacyclin,
was ﬁrst attributed to a non-characterized endothelial factor termed
EDHF [43–45]. The relative importance of the EDHF mediated mecha-
nisms to NO mediated mechanisms alters with vessel size [46]. NO is
an important endothelium-dependent mediator of vascular tone in rela-
tively large arteries and larger arterioles. At the level of the aorta, reduced
NObioavailability is proposed to be themainmarker for endothelial dys-
function. In resistance arteries, NO, prostacyclins and EDHFs are thought
to be involved in mediating endothelial function [47]. Alterations in
EDHF-mediated responses have been reported in diabetes [48]. Interest-
ingly, EDHF synthase/cytochrome P450 epoxygenase is also a source of
superoxide anion [52].
2. Endothelial dysfunction
In the earliest stages, the principal endothelial alteration is merely
functional. Functional impairment of the vascular endothelium is
found in all forms of cardiovascular disease [3,12] and also in people
with insulin resistance, obesity and type 2 diabetes [18]. The hallmark
of endothelial dysfunction is the impaired NO bioavailability. Addition-
ally, endothelial dysfunction is characterized by one or more of the
following features: reduced endothelium-mediated vasorelaxation,
hemodynamic deregulation, impaired ﬁbrinolytic ability, enhanced
turnover, overproduction of growth factors, increased expression of ad-
hesionmolecules and inﬂammatory genes, excessive generation of ROS,
increased oxidative stress, and enhanced permeability of the cell layer
[53–57].Numerous risk factors directly contribute to endothelial dysfunction.
Some of the more important are: elevated LDL cholesterol and oxidized
LDL; low high-density lipoprotein (HDL) cholesterol; elevated triglycer-
ides; hypertension; elevated C-reactive protein (CRP) and circulating li-
poprotein-associatedphospholipase A2 (Lp-PLA2— a speciﬁcmarker of
vascular inﬂammation); hyperglycemia; elevated omega-6:omega-3
ratio [58]; hyperinsulinemia; elevated homocysteine levels; increased
ﬁbrinogen and PAI-1; smoking; insufﬁcient vitamin D; among others
[59–61].
The presence of endothelial dysfunction has been implicated in the
pathogenesis of atherosclerosis and thrombosis, both for the loss of its
protective capability and for the induction of proatherothrombotic
mechanisms. The major features associated with endothelial dysfunc-
tion are summarized in Table 1.
2.1. The impact of diabetes on the vasculature
Diabetes is not only ametabolic disease but also considered as a vas-
cular disease because of its effect on macro and microcirculation of
many vascular beds. The link between diabetes and an increased inci-
dence of cardiovascular disease is well established [62,63]. Recent evi-
dence shows that etiopathogenesis of endothelial dysfunction differs
in types 1 and 2 diabetes [64]; it is present at the earliest stages of met-
abolic syndrome and insulin resistance, andmay precede the clinical di-
agnosis of type 2 diabetes by several years [65].
The metabolic milieu in diabetes (i.e. hyperglycemia, excess free
fatty acid release and insulin resistance) induces a vicious circle of
events in the vascular wall, involving increased endothelial dysfunction,
oxidative stress, low-grade inﬂammation and platelet hyperactivity, in
the early stages of diabetic disease. Thereby, activation of these systems
impairs endothelial function, augments vasoconstriction, increases in-
ﬂammation, and promotes thrombosis [62,63]. In Fig. 6 multiple mech-
anisms that promote atherogenesis are summarized.
Table 1
Differences between a healthy and a dysfunctional endothelium. Besides impaired
vasodilation (↓NO, PGI2), endothelial dysfunction is characterized by increase oxidative
stress (↑ nitrotyrosine and uric acid), pro-coagulant (↑PAI-1, vWF, P-selectin), and pro-
inﬂammatory biomarkers (↑sICAM, sVCAM, E-selectin, CRP, TNF-alpha, IL-6, MCP-1); dec-
rement in endothelial progenitor cells and increasedmolecular markers of damage (circu-
lating endothelial cells, microparticles, MPs).
CECs, circulating endothelial cells; CRP, C-reactive protein; EMPs, endothelial microparti-
cles; EPCs, endothelial progenitor cells; IL-6, interleukin-6; MPs, microparticles; NO, nitric
oxide; PAI-1, plasminogen activator inhibitor 1; PGI2, prostacyclin; ROS, reactive oxygen
species; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell ad-
hesion molecule; TNF-α, tumor necrosis factor alpha; vWF, von Willebrand factor.
Fig. 6. Severalmechanisms that foster endothelial dysfunction and vascular damage in type 2 dia
diabetic conditions. These factors include: hypertension, genetic predisposition, hyperglycemia,
tance and increased free fatty acids (FFAs) in circulation, lipemia, increased obesity as related to
enhanced proinﬂammatory and prothrombotic cytokines. Peripheral tissues are resistant to in
tance states, the pancreas initially tries to compensate by producing more insulin, resulting in
the liver with elevated levels of FFAs through the portal circulation. This excess of FFAs will lead
is accompanied by a concomitant decrease inHDL. The adipocyte can also release proinﬂammato
atherogenesis, but also can elicit the production of acute phase reactants by the liver, including C
ucts (AGEs) from glycated macromolecules can damage vasculature through different mechani
protein; and PAI-1, plasminogen activator inhibitor-1.
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Prolonged hyperglycemia and also transient, acute hyperglycemia
have been proven to impair endothelial function in bothmacro- andmi-
crovascular beds in animal studies and in human subjects [67–69]. Al-
though the effect of intensive glycemic control on the prevention of
macrovascular disease is less profound than on the reduction of micro-
vascular complications [70].
Hyperglycemia causes vascular damage in different cells of the vas-
cular wall (Table 2). The mechanisms are diverse and include: 1) in-
creased ﬂux of glucose and other sugars through the polyol pathway;
2) augmented intracellular formation of advanced glycation end prod-
ucts (AGEs); 3) increment in the expression of the receptor for AGEs
(RAGE) and its activating ligands; 4) activation of protein kinase protein
kinase C (PKC) isoforms; and 5) overactivation of the hexosamine path-
way [74]. The common pathway is oxidative stress. ROS decreases the
metabolism of glucose through glycolysis, and the ﬂux through the alter-
native polyol and hexosamine pathways is increased. Hyperglycemia
induced oxidative stress [71] leads to DNA damage and activation of
nuclear poly(ADP-ribose) polymerase (PARP) that in turn increases pro-
duction of polymers of ADP-ribose reducing glyceraldehyde 3-phosphate
dehydrogenase activity. Ultimately the levels of all upstream glycolytic
intermediates increase. The accumulation of glycolytic intermediates ac-
tivates damaging mechanisms: PKC pathway, hexosamine and polyol
pathways and AGE formation. The overall effects of these mechanisms
are increased oxidative stress, apoptosis and vascular permeability [74].
Additionally, glucotoxicity induces a low-grade proinﬂammatory
condition, due to the activation of transcription factors such as nuclearbetes. Various risk factors converge on the artery (center) to promote atherogenesis under
hyperinsulinemia, oxidative stress, advanced glycation end products (AGEs), insulin resis-
some factorswhich characterize life-style (sedentary, drinking, smoking and eatinghabits),
sulin action, which promotes hyperglycemia and increased levels of FFAs. In insulin resis-
hyperinsulinemia, itself a risk factor for angiopathy. High levels of abdominal fat present
to excess production of triglyceride (TG)-rich lipoprotein particles. Hypertriglyceridemia
ry cytokines such as TNF-α, which not only have direct effects on vascularwall promoting
RP, increased ﬁbrinogen and PAI-1. Finally, the formation of advanced glycation end prod-
sms. VLDL, very low-density lipoprotein; TNF-α, tumor necrosis factor-α; CRP, C-reactive
Table 2
Examples of mechanisms implicated in diabetic macrovascular disease.
Cellular players Mechanisms
Endothelial cells Increased reactive oxygen species
Decreased NO bioavailability
Increased harmful metabolites
(peroxynitrite, nitrotyrosine)
NF-κB activation
Increased lipid peroxidation products
Increased glycation (AGEs)
Impaired endothelial-dependent relaxation
Monocyte-derived
macrophages
Increased IL1β, IL6, CD36, MCP-1
Activation of protein kinase C
Vascular smooth muscle
cells
Increased proliferation
Increased migration into intima
Increased matrix degradation
Altered matrix components
(chondroitin, dermatan sulphate proteoglycans)
Increased nonenzymatic collagen glycation
Increased reactive oxygen species
AGEs — advanced glycation end products; IL — interleukin; MCP-1 — monocyte
chemoattractant protein-1; NF-κB — nuclear factor-kappa B; NO — nitric oxide.
• Insulin resistance
• NF- B 
• Decreased NO 
bioavailability
• Stress signaling
• Inflammation
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• PGIS nitration
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Fig. 7. Endothelial dysfunction in diabetes. Prolonged exposure to hyperglycemia is the
major culprit in the pathogenesis of diabetic complications, involving increased ROS and
RNS production. Oxidative stress leads to an imbalance in the vascular homeostasis due
to increased vasoconstriction and impaired vasorelaxation that ultimately fosters diabetic
endothelial dysfunction. AGEs, advanced glycation endproducts; EDCF, endothelium-derived
contracting factors; eNOS, endothelial nitric oxide synthase; FFAs, free fatty acids; PKC, pro-
tein kinase C; PGIS, prostacyclin synthase; NF-κB, nuclear factor-kappa B; NO, nitric oxide;
RNS, reactive nitrogen species; ROS, reactive oxygen species.
[167].
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multiple proinﬂammatory and proatherosclerotic target genes in en-
dothelial cells, VSMC, and macrophages. Activation of NF-κB leads to
an increased production of adhesion molecules, leukocyte-attracting
chemokines and cytokines activating inﬂammatory cells in the vas-
cular wall. A prothrombotic state is generated by the increased pro-
duction of lesion-based coagulants, such as tissue factor, and the
inhibitors of ﬁbrinolysis, such as PAI-1 (Table 1).
Vascular tone and remodeling are enhanced through reduced NO
and an increased activity and production of vasoconstrictors (ET-1,
angiotensin II, and prostanoids [74–76]) due to postprandial increases
in glucose, LDL cholesterol, and hyperinsulinemia (Fig. 7). Glucose may
also activate matrix-degrading metalloproteinases, enzymes implicated
in plaque rupture and arterial remodeling, inducing similar responses
in VSMC. Glucose may also stimulate VSMC proliferation, migration,
and altered reactivity, for example, through renin–angiotensin activation.
Elevated glucose can foster glycation of proteins, promoting forma-
tion of AGEs (Fig. 8), protein cross-linking, and ROS formation. Accumu-
lation of AGEs alters the functional property of matrix components and
mediates sustained cellular changes. Glycationmodiﬁes the structure of
the molecules and disturbs their function and receptor recognition
properties. In turn, binding of AGEs to their RAGE receptor increases in-
tracellular enzymatic superoxide production [79,80] and promotes
macrophage-mediated inﬂammation in the vessel wall [81]. AGEs also
decrease NO bioavailability and eNOS expression [82,83] and increase
expression of ET-1 in endothelial cells [84]; therefore altering the bal-
ance between NO and ET-1 to favor vasoconstriction and endothelial
dysfunction.
Thus, accelerated formation of multiple biochemical species under
hyperglycemic conditions such as nonenzymatic reactive Amadori
products, 3-deoxyglucosone, diacylglycerol, methylglyoxal [85], AGEs,
ROS, and nitrosylated species, greatly contributes to endothelial dys-
function in diabetes. The increased oxidative stress seems to be the
common alteration, triggered by a type 2 diabetes milieu, in which hy-
perglycemia is adjoined by insulin resistance, hyperinsulinemia, and
dyslipidemia [86].
2.1.2. Insulin resistance
Insulin resistance refers to a decreased ability of insulin to promote
glucose uptake in skeletalmuscle and adipose tissue and to suppress he-
patic glucose output [87]. Insulin signaling is transduced via two major
pathways: metabolic and hemodynamic effects are mediated by PI-3K
and the Ras–mitogen-activated protein kinase (MAPK) pathway is
mainly involved in gene expression regulation, cell growth anddifferen-
tiation [88]. Normally, insulin stimulates NO production in endothelialcells by activating NO synthase via the PI-3K pathway. In insulin resis-
tance (IR) this pathway is impaired, and the production of NO is dimin-
ished [89]. Instead, insulin resistance activates MAPK leading to
endothelial dysfunction. Insulin stimulates production of the vasocon-
strictor ET-1, and increases PAI-1 and cellular adhesion molecule
expression [90]. In addition to the direct effects of IR on the endotheli-
um, it also stimulates VSMC proliferation and migration and in adipose
tissue is associated with excessive release of free fatty acids (FFAs),
which evokes pathogenic gene expression through PKC activation and
increased oxidative stress [93]. IR- induced excess of FFAs is essential
also in the development of dyslipidemia, which further promotes the
development of a proatherogenic lipid proﬁle.
Ultimately, insulin resistance and type 2 diabetes are associated
with low-grade inﬂammation being reﬂected in increased serum
levels of tumor necrosis factor-α (TNF-α), interleukin-6, PAI-1, ET-
1 and high-sensitive C-reactive protein, also related to endothelial
dysfunction [98].
2.1.3. FFAs
Excessive release from adipose tissue and diminished uptake by skel-
etalmuscles increase circulating levels of FFAs in diabetes [99,100]. Acute
infusion of FFAs reduces endothelium-dependent vasodilation in animal
models and in humans in vivo [75,101].
Lipotoxicity by FFAsmay impair endothelial function by a number of
related mechanisms, including increased production of ROS, increase
AGE formation and activate PKC, the hexosamine pathway, and
proinﬂammatory signaling to the same extent as diabetic levels of
hyperglycemia. FFAs have been shown to induce ROS production in
the vasculature via mitochondrial uncoupling and by increasing the
expression and protein content of NADPH oxidases [74,93]. FFA-
induced overproduction of superoxide inactivates two important
antiatherogenic enzymes: prostacyclin synthase and eNOS. ROS
also decreases the concentration of intracellular glutathione and
makes vasculature more prone to oxidative damage.
Fig. 8.The formation of advanced glycation end products (AGEs) can involve early glucosemetabolites such as glyoxal andmethylglyoxal, highly reactive dicarbonyls and keyprecursors of
AGEs.
Table 3
Approaches to access oxidative stress in biological systems.
Approach Examples
Markers of
increased
pro-oxidant
activity
Increase in oxidant-generating systems
(NADPHoxidases, xanthine oxidase,mitochondrial ROS, NOS)
Direct measurements of ROS/RNS generation
(reduction of NBT, oxidant-sensitive dyes, direct radicals
measurement by ESR)
Markers of
decrease in
antioxidant
activity
Low-molecular-weight antioxidants
(vitamins C and E, GSH)
Antioxidant enzymes
(SODs, GPx, GR, catalase, thioredoxin system, paraoxonase)
Total antioxidant capacity
Resistant to an external oxidant
Altered cellular
redox state
Overall reducing activity (cyclic voltammetry)
GSH/GSSG ratio
Oxidative damage
parameters
Lipid oxidation (MDA, isoprostanes, 4-HNE)
Protein oxidation
(protein carbonylation, S-nitrosylation, nitrotyrosine,
glutathionylation)
DNA oxidation
(8-hydroxydeoxyguanosine, dihydropropidium iodide)
ROS, reactive oxygen species; RNS, reactive nitrogen species; NOS, nitric oxide synthase;
NADPH oxidases, nicotinamide adenine dinucleotide phosphate oxidases; NBT, nitroblue
tetrazolium; ESR, electron spin resonance; SOD, superoxide dismutase; GR, glutathione
reductase; GSH/GSSG, reduced glutathione/oxidized glutathione ratio; GPx, glutathione
peroxidase; 4-HNE, 4-hydroxynonenal; MDA, malondialdehyde.
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duction of other proinﬂammatory cytokines [103–105]. By activating
IKKα, FFA treatment impairs insulin stimulated activation of eNOS and
NO production in endothelial cells [106]. Activation of PKC by FFAs also
results in increased serine phosphorylation of IRS-1 that leads to reduced
insulin-stimulated activation of PI-3 kinase, phosphoinositide-dependent
kinase-1, Akt, and eNOS, and culminateswith impaired NO production in
endothelium [102,107]. Ultimately, FFAs stimulate endothelial apoptosis,
augment vascular oxidative stress, reduce NO bioavailability, enhance
endothelial and monocyte activation and increase inﬂammation [32].
The activation of metabolite sensitive pathways of vascular damage
by increased FFA ﬂux from insulin resistant visceral adipocytes to arte-
rial endothelial cells may be the metabolic link between insulin resis-
tance and macrovascular disease [74,94]. Increased oxidation of fatty
acids, derived in part from insulin resistance leads to oxidative stress
in diabetic macrovasculature, while in diabetic microvascular disease,
ROS are derived mainly from intracellular hyperglycemia [91,92]. In
both cases, under diabetic conditions oxidative stress seems to be the
common mechanism that triggers vascular dysfunction.
2.2. Oxidative stress
Oxidative stress describes the condition wherein an excessive pro-
duction of ROS overwhelms endogenous antioxidant defense mecha-
nisms. The resultant elevation in ROS levels has a detrimental effect
on cellular function, a consequence of ROS-induced damage to lipid
membranes, enzymes and nucleic acids [108].
Risk factors for cardiovascular disease (CVD), including type 2 diabe-
tes, are characterized by excess vascular production of ROS [108,109].
One of the earliest consequences of oxidative stress in human subjects
is impaired endothelium-dependent vasodilation [108]. Thus, accessing
oxidative stress in the vasculature could evaluate the risk for develop-
ment of vascular disease (Table 3).
2.2.1. Reactive oxygen species: major sources in the vasculature
All layers of the vascular wall have enzymatic systems capable of
producing ROS. ROS include the superoxide anion, the hydroxyl radical,
NO, lipid radicals, hydrogen peroxide (H2O2), hypochlorous acid and
peroxynitrite [108].
The most important sources of ROS generation in the vasculature
include the mitochondrial electron transport chain [114–116], NADPH
oxidases [117–119] and xanthine oxidase [108,120]. In addition,uncoupled eNOS and enzymes, such as lipoxygenase and cyclooxy-
genase, cytochrome P450s, peroxidases and other hemoproteins
[108] are sources of ROS.
2.2.1.1. NADPH oxidases.NADPH oxidases are multicomponent enzymes
functional inmembranes of various cell types including endothelial cells
and smooth muscle cells. NADPH family is the predominant source of
O2•− in the human vasculature [117,119]. Of the seven Nox isoforms
discovered, only Nox1, Nox2, Nox4 and Nox5 are expressed in blood
vessels, with different cell-speciﬁc expressions, mode of activations
and functions (for a review see [110,112]).
Activation of NADPH oxidases in the vasculature occurs in response
to angiotensin II, other vasoactive hormones (e.g., ET-1), growth factors
(e.g., transforming growth factor-β), cytokines, and mechanical stimuli
(shear stress and stretch), among others [121,110]. Evidences from the
literature clearly point to a role of Nox isoforms in vascular disease
although their relative contribution remains unclear [110]. Nox1 and
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[112]. Recent data suggest an important role for Nox1 in diabetes-
associated atherosclerosis [111]. Sukumar and co-workers showed
that endothelial cell-speciﬁc insulin resistance increases Nox2 expres-
sion and leads to O2•− generation in endothelial cells sufﬁcient to foster
arterial dysfunction [122,225]. Contrary to Nox1 and Nox2, expression
of Nox4 was recently suggested to be vasculoprotective [112,113]. Ap-
parently, under ischemia, hypertension or inﬂammatory stress Nox4-
derived H2O2 was suggested to have a protective role [112,113]. Finally,
Nox5 (an isoform expressed in humans but not in rodents) is also able
to generate ROS in blood vessels and seems to have a role in endothelial
and VSMC growth [112].
2.2.2. Endothelial nitric oxide synthase
Nitric oxide generation is dependent on eNOS homodimerization in
the presence of BH4. However, BH4 is highly susceptible to oxidative
degradation by ONOO− and in the absence of its cofactor, eNOS fails to
dimerize fully, resulting in uncoupling of the enzyme and ampliﬁcation
of oxidative stress and generation of O2•− rather than NO [73].
Uncoupled eNOS has been shown to contribute to increased superoxide
production and endothelial dysfunction in a number of CVD, including
coronary artery disease [129] and type 2 diabetes [130].
2.2.3. Mitochondria
Enzymes of the inner mitochondrial membrane transfer electrons
along the electron transport chain which generates a proton gradient,
enabling ATP synthase to generate ATP. Under physiological conditions,
this process produces ROS as byproducts [116,131,132]. Several mito-
chondrial antioxidant systems are in place to protect against ROS-
induced damage to mitochondrial proteins, lipids and nucleic acids.
However, under conditions of oxidative stress, these antioxidant sys-
tems are overwhelmed, allowing ROS to exert their deleterious effects
and ultimately change mitochondrial function [116,131,134].
2.3. Mechanisms of defense against oxidative stress
The vasculature is endowed with protective antioxidant defense
mechanisms, both enzymatic and nonenzymatic, to counteract the det-
rimental effects of ROS. Non-enzymatic antioxidant molecules include
ascorbic acid (vitamin C), α-tocopherol (vitamin E) and glutathione,
while superoxide dismutases (SODs), catalase, glutathione peroxidases
(GPxs) and thioredoxins represent important antioxidant enzymes
which act to directly scavenge ROS, converting them to less reactive
species [138–140].
2.3.1. Superoxide dismutases
The SODs represent the ﬁrst and most important line of enzymatic
antioxidant defense against ROS. A ubiquitous family of enzymes,
SODs catalyzes the conversion of O2•− to H2O2 and O2 [138,139,141].
Three distinct isoforms of SOD have been identiﬁed in vascular tissue:
Cu/Zn SOD (encoded by SOD1 gene) is located in the cytoplasm,
MnSOD (encoded by SOD2 gene) in the mitochondria and extracellular
SOD (encoded by SOD3 gene).
The importance of SODs as an antioxidant defense mechanism has
been highlighted by gene transfer studies wherein SOD overexpression
improved endothelial function [142,143]. Overexpression of SOD2 has
also been shown to prevent hyperglycemia-associated production of
O2•−, activation of PKC and AGE formation [144], supporting a role for
mitochondrial ROS production in diabetic macrovascular disease.
2.3.2. Catalase
Catalase is a highly catalytically efﬁcient enzyme, primarily located
in peroxisomes but also functions in the cytosol and catalyzes the con-
version of H2O2 to water following dismutation of O2•− by SOD
[138,139,145]. Inherited catalase deﬁciency has been linked to elevated
cardiovascular risk and increased incidence of diabetes mellitus [139].However, experimental investigation has provided evidence that cata-
lase provides only moderate protection against oxidative stress [146].
2.3.3. Glutathione peroxidases
GPxs are a family of enzymes with an important role in antioxidant
defense. Like catalase, GPxs reduceH2O2 towater and lipid hydroperox-
ides to their corresponding alcohols. Detoxiﬁcation of secondary oxida-
tion products is vital and GPxs play an important role, reducing lipid
peroxides [138,139,147].
There are several isozymes, GPx1 is the most abundant form in
mammalian tissues. Mice with a disrupted GPx1 gene exhibit increased
susceptibility to oxidative stress-inducing agents [148], while induction
of this isozyme has been shown to provide protection against oxidative
damage in endothelial cells [149]. In apoE-deﬁcientmice, the deﬁciency
of GPx1 accelerates and modiﬁes atherosclerotic lesion progression
[31,150]. Furthermore, transgenic GPx1 expressionwas observed to im-
pair endothelial dysfunction [151]. Similarly, deﬁciency of GPx3 has
been associated with decreased NO bioavailability and increased
platelet-dependent thrombosis [139]. GPx4 knockout mice are not via-
ble; they die during early embryonic development.
Glutathione is the principal lowmolecular weight, non-protein thiol
in the cell [138]. Mainly found in the reduced state, glutathione has nu-
merous functions in metabolism, signal transduction and gene expres-
sion [152]. GSH acts as an electron donor and can directly scavenge
ROS but also acts as a cofactor in the conversion of H2O2 to H2O by
GPxs [138,139].
Additional selenoproteins with similar antioxidant activities to GPxs
include the thioredoxins [139], while the glutathione-S-transferases
(GSTs) are examples of nonselenocysteine containing enzymes of
signiﬁcant importance in secondary oxidative stress defense, acting to
detoxify reactive electrophiles [139,147].
2.3.4. Thioredoxin
Thioredoxin (Trx) seems to exert most of its ROS-scavenging
properties through Trx peroxidase (peroxiredoxin), which uses en-
dogenous SH groups as reducing equivalents. Thioredoxin is present
in endothelial- and vascular smooth muscle cells. Trx scavenges ROS
and ONOO− and also reduce disulﬁdes in proteins, peptides, and ox-
idized glutathione (GSSG) [140,153].
2.3.5. Heme oxygenase
Heme oxygenase (HO) has indirect antioxidant effects through
breakdown of free heme and the production of carbon monoxide, as
well as biliverdin and bilirubin, which themselves have antioxidant
properties [154]. There are two isoforms of this enzyme, a constitutive
heme oxygenase, HO2, which is ubiquitously expressed in endothelial
cells, and HO1, which is induced in response to oxidative stress, proba-
bly as an adaptive response. There is extensive evidence that HO1 can
protect against vascular damage and atherogenesis [14,124,155]. The
carbon monoxide has antiproliferative and anti-inﬂammatory as well
as vasodilatory properties [156]. Genetic models of HO1 deﬁciency or
overexpression of HO1 suggest that the actions of HO1 are important
in modulating the severity of atherosclerosis [157].
2.3.6. Paraoxonase
The paraoxonase (PON) family of enzymes acts as vascular antioxi-
dant defense and protects against vascular disease [158]. The PON1
and PON3 enzymes are synthesized in the liver and circulate in plasma
associated with HDL. The capacity of HDL in decreasing HDL and LDL
lipid peroxidation largely depends on its PON1 content [158].
PON1 knockout mice are more prone to atherosclerosis [159] and
low PON1 activity predicts acute cardiovascular events in human
prospective studies [160]. Deletion of PON1 gene increases oxidative
stress in mouse macrophages [161]. PON2 is expressed in many cell
types. The enzyme has been shown to reduce ROS in human endo-
thelial cells and vascular smooth muscle cells [162]. PON2-deﬁcient
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lesions, whereas PON2-overexpressing mice were protected against
those lesions [163].
Diabetes is characterized by increased oxidative stress and by de-
creased PON1 activity [164]. The ability of PON1 to protect against oxi-
dative stress involved in major diseases such atherosclerosis and
diabetes underlines the notion that strategies aimed at increasing
PON1 activity and/or expression would have several beneﬁts.
3. Potential therapeutic targets
In type 2 diabetes, glucotoxicity, lipotoxicity, insulin resistance and a
mutual interaction between these factors occur to foster the develop-
ment and progression of endothelial dysfunction. Conventional thera-
pies to reduce hyperglycemia, dyslipidemia and insulin resistance
represent important clinical options to improve endothelial function
and delay the progression of vascular complications [165]. These con-
ventional therapies and their effect on vascular function have been eval-
uated and reviewed elsewhere [166–169]. Noteworthy, most of these
therapies are not completely effective in slowing vascular disease and
would beneﬁt from adjuvant cardiovascular protective therapies.
3.1. Cardiovascular therapies targeting the endothelium
The endothelium is a highly important target for therapy in cardio-
vascular disease [170]. It is rapidly and preferentially exposed to system-
ically administered agents and establishes a link with the underlying
tissue, providing the researcher with a useful therapeutic target.
3.1.1. Potential therapeutic options for treating endothelial dysfunction by
modulating eNOS
The vascular tone of arteries is primarily controlled by the bioavail-
ability of NO, a key factor in vascular protection by preserving vessel
reactivity. Thus,multiple potential therapeutic targets have been identi-
ﬁed along the L-arginine–NOS pathway that could increase NO bioavail-
ability. In Fig. 9 these sites are identiﬁed and include: at the level of the
substrate, L-arginine; at the level of the NO-generating enzyme, eNOS;
at the level of the soluble guanylyl cyclase, its main target; and at the
level of the main effector of NO action, cGMP [5].
Administration of NO donors such as pentaerythritol tetranitrate
(PETN) reduces oxidative stress (probably by inducing HO1) and im-
proves endothelial dysfunction [135]. Thus, diabetic patients would
beneﬁt greatly from organic nitrate treatment devoid of classical ad-
verse effects, such as nitrate-induced vascular oxidative stress, nitrate
tolerance, and endothelial dysfunction (cross-tolerance) [125].
NO availability can be increased augmenting NO production by
eNOS. The simplest way to modulate eNOS is administration of its
substrate L-arginine [126] or its essential cofactor BH4 or BH4 analogs
(Figs. 9, 10). Folic acid and its active form 5-methyltetrahydrofolate
can modulate eNOS by improving BH4 bioavailability in the vasculature
bypreventing its oxidation [218].Midostaurin, betulinic acid and ursolic
acid upregulate eNOS and simultaneously decrease NADPH oxidase
expression. Novel small molecules AVE9488 and AVE3085 are two
eNOS transcription enhancers that reverse eNOS uncoupling and pre-
serve eNOS functionality and consequently increase NO bioavailability
[136,171]. There is evidence that a cell-permeable peptide antagonizes
the inhibitory actions of caveolin-1 on eNOS leading to increase in NO
production [217]. Statins, angiotensin II type 1 receptor blockers, estro-
gens and erythropoietin enhance BH4 synthesis by stimulating GTP
cyclohydrolase I (GCH1) expression or activity. In vivo activation of
AMP-activated protein kinase (AMPK) normalizes endothelial function
due to an inhibition of GCH1 degradation associated with diabetes
[137]. Statins, angiotensin II receptor blockers, ACE inhibitors, the aldo-
sterone antagonist eplerenone and the renin inhibitor aliskiren prevent
BH4 oxidation by decreasing the expression and/or activity of NADPH
oxidase (Figs. 9, 10). Statins can also directly activate eNOS via post-translationalmechanisms involving activation of the phosphatidylinositol
3-kinase/protein kinase Akt pathway [172].
In addition, cGMP levels may also be increased by inhibiting its me-
tabolism by the phosphodiesterase-5 (PDE5) enzyme. The strategy of
increasing the downstreammediator cGMP without affecting NO levels
may be preferred due to the mixed outcomes in stroke reported in ani-
mal models following alterations in NO levels [173].
sGC stimulators and activators can treat the 2 forms of sGC insufﬁ-
ciency (i.e., diminished NO bioavailability and reduction of the catalytic
capacity of sGC). Preliminary studies with both PDE5 inhibitors and
sGC-targeted drugs have shown promising results [174–176].
3.1.2. Therapeutic approaches to reduce oxidative stress and/or increase
antioxidant defense systems
Given the crucial role of ROS in endothelial function, considerable
efforts have been made to discover therapies to reduce ROS in the vas-
culature. Despite promising initial observations, clinical trials with anti-
oxidant vitamins C and E failed to show an improved cardiovascular
outcome. Eventually new antioxidant molecules, targeted to the precise
locations where ROS concentrations are elevated may, at an early stage,
inhibit the mechanisms leading to diabetic complications [177].
The ability of PON1 to protect against oxidative stress and hydrolyze
homocysteine thiolactone, a metabolite of homocysteine that can im-
pair protein function promoting endothelial dysfunction, underlines
the notion that strategies aimed at increasing PON1 activity and/or
expression can be beneﬁcial. Certain drugs (e.g. hypolipemic and
antidiabetic compounds), dietary and life-style factors (e.g. antioxidants,
polyphenols, moderate wine consumption) appear to increase PON1
activity [180,195]. Promoting an increment in PON1 activity may prove
beneﬁcial to prevent diabetes development [229] and slow down its car-
diovascular complications [180,181,230].
Substances able to inhibit NADPH oxidases and prevent superoxide
production may be useful for treatment of endothelial dysfunction
[224]. Several inhibitors of the NADPH oxidase have been developed to
speciﬁcally target NADPH oxidases with potential beneﬁts [182–184,
reviewed in 110 and 112]. Many cardiovascular drugs interfere with
NADPHoxidases althoughmost likely by indirectmechanisms. Addition-
ally, ﬂavonoids exhibit an inhibitory effect on NADPH oxidase combined
with O2•− scavenging [184]. Nox-signaling pathways in the vasculature
are likely to offer novel therapies. Discovering gene therapy targets to-
wards enzymes involved in the homeostasis of vascular redox state is es-
sential. Recently, the design and application of nanocarriers for delivery
of antioxidants to the endothelium was performed with favorable out-
comes [178]. Additionally, it has been described that delivery of genes
encoding antioxidant defense enzymes (e.g. superoxide dismutase, cata-
lase, glutathione peroxidase, PON1orHO1) or eNOS suppress atherogen-
esis in animal models [49–51,66,97,123]. Similarly, delivery of genes
encoding regulators of redox sensitive transcriptional factors (e.g. NF-
kappa B, AP-1, and NF-E2-related factor-2) or reactive oxygen species
scavengers has been successfully used in experimental studies [72,179].
Induction of endogenous antioxidant enzymes by activators of the
NF-E2-related factor-2/antioxidant response element pathway may be
an interesting approach to obtain sufﬁcient levels of antioxidants and
reduce oxidative stress [72,77]. Additionally, SIRT1-mediated inhibition
of p66Shc (a key effector driving vascularmemory in diabetes)may also
contribute to the prevention of oxidative stress-induced endothelial
dysfunction in vascular diseases [78]. Despite the promising results
from basic science, the clinical applicability of these strategies has prov-
en to be difﬁcult and challenging.
3.2. Other therapeutic approaches
Novel therapeutic approaches designed to inhibit AGE formation
and signaling (Fig. 11) [185,186], speciﬁcally directed to reduce inﬂam-
mation [187,226] and restore the ox/redox balance in the endothelium
may represent promising strategies to ameliorate vascular function in
Fig. 9. Potential sites of therapeutic intervention in the L-arginine–NO-synthase–soluble guanylyl cyclase pathway. They are indicated by numbers (from 1 to 14). The schematic diagram
shows an endothelial cell in yellow and a vascular smooth muscle cell in light pink. The numbers indicate: (1) L-arginine supplementation. (2) Inhibition of protein arginine N-
methyltransferase type I (PRMT-I) to prevent the formation of asymmetric dimethyl-L-arginine (ADMA). (3) Increasing the expression and/or the activity of dimethylarginine
dimethylaminohydrolase (DDAH) to increase ADMAdegradation. (4) Inhibition of arginase-2 to preclude L-argininemetabolism. (5) Increasing the expression and/or activity of endothe-
lial nitric oxide synthase (eNOS). (6) Stimulation of endothelium-derived nitric oxide release. (7) Enhancing the expression and/or activity of guanosine triphosphate cyclohydrolase
(GCH1), to increase tetrahydrobiopterin synthesis (BH4), or direct supplementation with BH4, or with its precursors. (8) Enhancing the expression and/or activity of dihydrofolate reduc-
tase (DHFR), to increase BH4 regeneration. (9) Scavengers of reactive oxygen species (ROS). (10) Inhibition of the activity and/or expression of enzymes that generate ROS such as NADPH
oxidases (NOX), cyclooxygenases (COX), lipoxygenases (LOX) or cytochrome P450 monoxygenases (P450). (11) Enhancing the expression and/or activity of enzymes that metabolized
ROS such as superoxide dismutase (SOD) or glutathione peroxidase. (12) Activators of soluble guanylyl cyclase (sGC). (13) Activators of sGC. (14) Inhibitors of phosphodiesterase-5 (PDE-
5). BH2, dihydrobiopterin; CAT-1, cationic amino acid transporters; CaV, voltage-activated calcium channel; cGMP, cyclic guanosine monophosphate; FAD, ﬂavin adenine dinucleotide;
FMN, ﬂavin mononucleotide; O2•−, superoxide anion; ONOO−, peroxynitrite; PKG, protein kinase G.
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inhibitors, PARP inhibitors and rho-associated coiled-coil protein kinase
(ROCK) inhibitors, among others.
AMPK is recognized as a key regulator of cellular energy status that
has favorable effects on eNOS activity, insulin sensitivity, and mitochon-
drial function in a variety of cell types, including vascular cells. Therefore,
pharmacological therapeutics that activate AMPK can be an important
target in treating vascular complications in diabetes [137,219].
Inhibition of protein kinase C is another therapeutic approach.
LY333531 (ruboxistaurin mesylate) has been shown to reduce oxidative
stress and inﬂammation by blocking PKC-β isoform activation [188]. This
inhibitory approach may also decrease vascular insulin resistance [133].
Furthermore, chronic treatment with the PARP inhibitors in rodent
models has been demonstrated to improve endothelial dysfunction as-
sociated with aging [189,191]. In addition, pharmacological inhibition
of PARP with PJ-34 restored endothelium-dependent vasodilation and
reduced the levels of cytokines and inﬂammatory response [192,193].
Additionally, PARP-1 knockout protects against dyslipidemia-induced
autonomic and vascular dysfunction in ApoE−/− mice [194]. PARP in-
hibitors are potential therapies for diabetic vasculopathy. Pharmacolog-
ical catalytic decomposition of peroxynitrite with FP15 has been
demonstrated to effectively eliminate peroxynitrite and prevent PARP
activation both in vitro and in vivo [220,221], thereby improving cardio-
vascular function in various disease models.Rho-associated coiled-coil protein kinases are potential targets for
treatment in vascular disease as suggested by the use of speciﬁc inhibi-
tors as fasudil. Treatment with fasudil was protective against vascular-
injury-induced leukocyte recruitment in wild type but not eNOS KO
mice [222]. In diabetic animal models, studies have demonstrated a sig-
niﬁcant correlation between increased RhoA activity and impaired vas-
cular function [223]. Thus, testing of fasudil and newer more speciﬁc
second generation ROCK inhibitors in a diabetic setting would be of
great interest in an effort to limit vascular complications [95].
Overall it is important to identify new targets for therapy and devel-
op new agents for clinical use.
3.3. Targeting vascular disease risk factors with nutritional therapeutics
Several nutritional agents such as lipoic acid, polyphenols, resvera-
trol, pomegranate, omega-3 fatty acids and bioavailable SOD have
been shown to effectively improve and/or protect against endothelial
dysfunction. Indeed, a comprehensive nutritional regimen can be
adjoined with pharmacological approaches in order to target all of the
risk factors that contribute to atherosclerosis.
Lipoic acid (LA) is a naturally occurring antioxidant that serves as a
coenzyme in energy metabolism of fats, carbohydrates, and proteins.
It can regenerate thioredoxin, vitamin C, and glutathione, which in
turn can recycle vitamin E. LA reduces serum glucose levels in diabetic
Fig. 10. Focus on the potential eNOS-based therapeutic approaches for endothelial dysfunction. The essential NOS cofactor tetrahydrobiopterin (BH4) is synthesized from guanosine 5′-
triphosphate (GTP) via a de novo pathway by the rate-limiting enzymeGTP cyclohydrolase I (GCH1). Alternatively, the synthesis of BH4 can occur via other pathways including the salvage
pathway, from dihydrobiopterin (BH2) back to BH4. As a substrate, L-arginine stimulates NO release from eNOS. Folic acid may improve eNOS functionality by stabilizing BH4 and stimu-
lating the endogenous regeneration of BH2 back to BH4. Midostaurin, betulinic acid and ursolic acid upregulate eNOS and simultaneously decrease NADPH oxidase expression. AVE9488
and AVE3085 are two eNOS transcription enhancers that reverse eNOS uncoupling and improve eNOS functionality. Statins, angiotensin II type 1 receptor blockers (ARBs), estrogens and
erythropoietin (EPO) enhance BH4 synthesis by stimulating GCH1 expression or activity. Statins, ARBs, angiotensin-converting enzyme (ACE) inhibitors, the aldosterone antagonist
eplerenone and the renin inhibitor aliskiren prevent BH4 oxidation by decreasing the expression and/or activity of NADPH oxidase.
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abolic syndrome [196]. In type 2 diabetic animalmodels, we have previ-
ously shown a reduction of endothelial dysfunction after treatment
with LA [21].
Different natural polyphenols have been shown to preserve endo-
thelial function and prevent cardiovascular disease. Epidemiological ev-
idence suggests a negative correlation between the consumption of
polyphenol-rich foods (fruits, vegetables, and cocoa contained in choc-
olate) or beverages (wine, especially red wine, grape juice, green tea,
among others.) and the incidence of cardiovascular disease [197–199].
Most polyphenols are mild antioxidants, some can reduce the
activity of prooxidative NADPH oxidases, and others can stimulate
antioxidative enzymes and eNOS [200–203]. The beneﬁcial effects
of silibinin on ADMA levels and endothelial dysfunction in db/db
mice were recently described. The endothelium-dependent vasodi-
latation to ACh was impaired in db/db mice and was restored in the
silibinin group, accompanied with a reduction of plasma and vascu-
lar levels of ADMA [128].
Several molecules with antioxidant properties (such as resveratrol,
piceatannol, probucol, taurine) enhance dimethyl arginine dimethyl
amino hydrolase activity, increasing ADMA catabolism [127].The beneﬁts of resveratrol include improvements in endothelial
function [204–206]. Resveratrol seems to increase the number and
activity of endothelial progenitor cells [205]. Resveratrol beneﬁts the
circulatory system by eliciting a decrease in the oxidation of LDL; by fos-
tering decreases in platelet aggregation; and by promoting relaxation of
arterioles [207]. Thus, resveratrol improves cardiovascular system by
decreasing factors that contribute to the development of atherosclerosis
and atherothrombosis [96,208].
Previous studies indicate that pomegranate and its extracts reduce
oxidation and inﬂammationmainly through their effect on PON-1 activ-
ity, intervening at each step in the development of atherosclerosis
[209–211].
Intake of omega-3 fatty acids might reduce Lp-PLA 2 levels and
reduce the risk of vascular disease [212,213]. Omega-3 fatty acids
serve as substrates for the conversion to a novel series of lipidmediators
designated resolvins and protectins, with potent anti-inﬂammatory
properties [187]. Studies have found that when omega-3 fatty acids
were combined with rosuvastatin or other conventional therapies, the
combination improved endothelial function [214,215].
Diminished levels of the antioxidant enzyme SOD have been linked
with cardiovascular disease. Supplementation with GliSODin, a vegetal
Fig. 11. Potential sites of therapeutic intervention in order to reduce hyperglycemia and its downstream effects. On the left there are the potential target sites: glycemic control; glycosyl-
ation inhibition; crosslink breakers; RAGEblockers; blocking of PKC signaling pathway; and blocking of apoptosis. AGEs, advanced glycation end products;MAPK,mitogenic activated pro-
tein kinase; PKC, protein kinase C; RAGE, receptor for advanced glycation end products.
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ness of the carotid artery intima and media layers as measured by
ultrasonography-B [216]. Previous studies have demonstrated the
preventive efﬁcacy of GliSODin at a preclinical stage in subjects
with risk factors of cardiovascular disease.
4. Conclusions
Endothelial function is important for the homeostasis of the body
and its dysfunction is associated with several pathophysiological condi-
tions, including atherosclerosis, hypertension and diabetes. Under-
standing and treating endothelial dysfunction is a major issue in the
prevention of vascular complications associatedwith all forms of diabe-
tes mellitus.
Controlling a variety of risk factors causing inﬂammation and oxida-
tive stress with combination therapy targeting intracellular mechanisms
underlying metabolic alterations (such as inhibiting AGE formation and
signaling and suppressing PKC activation) may simultaneously address
multiple mechanisms underlying the pathogenesis of atherosclerosis.
Since therapy addressing a single metabolic abnormality has not been
effective, to reduce cardiovascular complications in type 2 diabetes may
require simultaneous interventions within multiple metabolic and sig-
naling pathways. Concurrent reduction of hyperglycemia, oxidative
stress, inﬂammation and insulin resistance may be necessary to amelio-
rate the adverse effects that progress to diabetic vasculopathy in patients
with cardiovascular risk factors.Acknowledgements
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